1. 4283Impact of primary hemostasis disorders on late (>30 days) major/life-threatening bleedings after TAVR. (28th August 2018) Authors: Kibler, M; Marchandot, B; Nathan, N; Vincent, F; Grunebaum, L; Crimizade, U; Kindo, M; Hoang, M T; Petit-Eisenmann, H; Jesel, L; Susen, S; Van Belle, E; Ohlmann, P; Morel, O Journal: European heart journal Issue: Volume 39(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P2Y12 inhibition by clopidogrel increases adverse clinical outcomes in patients undergoing transcatheter aortic valve replacement. (25th November 2020) Authors: Matsushita, K; Marchandot, B; Kibler, M; Sato, C; Heger, J; Peillex, M; Trimaille, A; Hess, S; Grunebaum, L; Ohana, M; Reydel, A; Jesel, L; Ohlmann, P; Morel, O Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Predictive impact of PVL assessments on clinical outcomes in patients undergoing TAVR. (25th November 2020) Authors: Matsushita, K; Marchandot, B; Kibler, M; Sato, C; Heger, J; Peillex, M; Trimaille, A; Hess, S; Grunebaum, L; Ohana, M; Reydel, A; Jesel, L; Ohlmann, P; Morel, O Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Primary hemostatic disorders drive early and late major bleedings of patients with atrial fibrillation after transcatheter aortic valve replacement. (14th October 2021) Authors: Matsushita, K; Marchandot, B; Hess, S; Kibler, M; Sato, C; Heger, J; Truong, D P; Trimaille, A; Sattler, L; Grunebaum, L; Reydel, A; Jesel, L; Ohlmann, P; Morel, O Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗